4151 Stock Overview
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide.
No risks detected for 4151 from our risk checks.
Kyowa Kirin Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||JP¥3,150.00|
|52 Week High||JP¥4,240.00|
|52 Week Low||JP¥2,604.00|
|1 Month Change||0.64%|
|3 Month Change||19.82%|
|1 Year Change||-8.96%|
|3 Year Change||72.60%|
|5 Year Change||63.98%|
|Change since IPO||138.64%|
Recent News & Updates
|4151||JP Pharmaceuticals||JP Market|
Return vs Industry: 4151 underperformed the JP Pharmaceuticals industry which returned 6% over the past year.
Return vs Market: 4151 underperformed the JP Market which returned -0.1% over the past year.
|4151 Average Weekly Movement||3.7%|
|Pharmaceuticals Industry Average Movement||4.1%|
|Market Average Movement||3.9%|
|10% most volatile stocks in JP Market||8.1%|
|10% least volatile stocks in JP Market||2.1%|
Stable Share Price: 4151 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 4151's weekly volatility (4%) has been stable over the past year.
About the Company
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent.
Kyowa Kirin Fundamentals Summary
|4151 fundamental statistics|
Is 4151 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|4151 income statement (TTM)|
|Cost of Revenue||JP¥89.98b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 04, 2022
|Earnings per share (EPS)||115.90|
|Net Profit Margin||16.72%|
How did 4151 perform over the long term?See historical performance and comparison
1.5%Current Dividend Yield
Does 4151 pay a reliable dividends?See 4151 dividend history and benchmarks
|Kyowa Kirin dividend dates|
|Ex Dividend Date||Dec 29 2022|
|Dividend Pay Date||Mar 28 2023|
|Days until Ex dividend||143 days|
|Days until Dividend pay date||232 days|
Does 4151 pay a reliable dividends?See 4151 dividend history and benchmarks
Is 4151 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4151?
Other financial metrics that can be useful for relative valuation.
|What is 4151's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 4151's PE Ratio compare to its peers?
|4151 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
4528 Ono Pharmaceutical
4578 Otsuka Holdings
4151 Kyowa Kirin
Price-To-Earnings vs Peers: 4151 is good value based on its Price-To-Earnings Ratio (27.2x) compared to the peer average (28.4x).
Price to Earnings Ratio vs Industry
How does 4151's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 4151 is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the JP Pharmaceuticals industry average (18.1x)
Price to Earnings Ratio vs Fair Ratio
What is 4151's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||27.2x|
|Fair PE Ratio||25x|
Price-To-Earnings vs Fair Ratio: 4151 is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the estimated Fair Price-To-Earnings Ratio (25x).
Share Price vs Fair Value
What is the Fair Price of 4151 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4151 (¥3150) is trading below our estimate of fair value (¥4620.8)
Significantly Below Fair Value: 4151 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Kyowa Kirin forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4151's forecast earnings growth (11.3% per year) is above the savings rate (0.04%).
Earnings vs Market: 4151's earnings (11.3% per year) are forecast to grow faster than the JP market (8.7% per year).
High Growth Earnings: 4151's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4151's revenue (5.4% per year) is forecast to grow faster than the JP market (4.4% per year).
High Growth Revenue: 4151's revenue (5.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4151's Return on Equity is forecast to be low in 3 years time (8.9%).
Discover growth companies
How has Kyowa Kirin performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4151 has high quality earnings.
Growing Profit Margin: 4151's current net profit margins (16.7%) are higher than last year (13.6%).
Past Earnings Growth Analysis
Earnings Trend: 4151's earnings have grown by 5.4% per year over the past 5 years.
Accelerating Growth: 4151's earnings growth over the past year (40.6%) exceeds its 5-year average (5.4% per year).
Earnings vs Industry: 4151 earnings growth over the past year (40.6%) exceeded the Pharmaceuticals industry 17.2%.
Return on Equity
High ROE: 4151's Return on Equity (8.1%) is considered low.
Discover strong past performing companies
How is Kyowa Kirin's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 4151's short term assets (¥523.3B) exceed its short term liabilities (¥103.5B).
Long Term Liabilities: 4151's short term assets (¥523.3B) exceed its long term liabilities (¥70.9B).
Debt to Equity History and Analysis
Debt Level: 4151 is debt free.
Reducing Debt: 4151 has no debt compared to 5 years ago when its debt to equity ratio was 0.9%.
Debt Coverage: 4151 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 4151 has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Kyowa Kirin current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Cash Flow Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 4151's dividend (1.52%) isn’t notable compared to the bottom 25% of dividend payers in the JP market (1.63%).
High Dividend: 4151's dividend (1.52%) is low compared to the top 25% of dividend payers in the JP market (3.62%).
Stability and Growth of Payments
Stable Dividend: 4151's dividends per share have been stable in the past 10 years.
Growing Dividend: 4151's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (40.5%), 4151's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (40.2%), 4151's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Masashi Miyamoto (63 yo)
Mr. Masashi Miyamoto Ph D., serves as Representative Director at Kyowa Kirin Co., Ltd. He serves as President of Kyowa Hakko Kirin Co., Ltd since March 2018, served as a Chief Operating Officer since March...
Experienced Management: 4151's management team is considered experienced (3.4 years average tenure).
Experienced Board: 4151's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Kyowa Kirin Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Kyowa Kirin Co., Ltd.
- Ticker: 4151
- Exchange: TSE
- Founded: 1949
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: JP¥1.680t
- Shares outstanding: 537.47m
- Website: https://www.kyowakirin.com
Number of Employees
- Kyowa Kirin Co., Ltd.
- Otemachi Financial City Grand Cube
- 1-9-2, Otemachi
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/08 00:00|
|End of Day Share Price||2022/08/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.